Zealand Pharma A/S (ZEAL.CO) stock: key figures, P/E, revenue and dividend
Health Care · Denmark · ISIN DK0060257814
Zealand Pharma A/S financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 62.00 m DKK | 9.21 bn DKK |
| Gross profit | 54.00 m DKK | 9.19 bn DKK |
| Operating income | -1.27 bn DKK | 6.92 bn DKK |
| EBIT | -1.27 bn DKK | 7.16 bn DKK |
| Net income | -1.08 bn DKK | 6.46 bn DKK |
| Diluted EPS – continuing operations | -15.27 DKK | 91.42 DKK |
Full history since 2007, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
More stocks
- Verallia SA (VRLA.PA)
- Inari Amertron Bhd (0166.KL)
- OSB Group PLC (OSB.L)
- Shanghai Xinhua Media Co Ltd (600825.SS)
- S-1 Corp (012750.KS)
- Inversiones la Construccion S.A. (ILC.SN)
- Lakala Payment Co Ltd (300773.SZ)
- An Hui Wenergy Co Ltd (000543.SZ)
- Fulltech Fiber Glass (1815.TWO)
- EZCORP INC (EZPW)
- Elmos Semiconductor (ELG.DE)
- EURONET WORLDWIDE, INC. (EEFT)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.